Bulk Pharmaceutical API Sources for FERRLECIT

Bulk Pharmaceutical API Sources for FERRLECIT

Vendor	Vendor Homepage	Vendor Sku	API Url
J&H Chemical Co.,ltd		JH264231
Starshine Chemical		2023-05-9C03158

FERRLECIT API Sourcing Landscape

Last updated: February 19, 2026

This analysis details the patent landscape and commercial sourcing options for bulk Active Pharmaceutical Ingredient (API) of FERRLECIT (Sodium Ferric Gluconate Complex). The focus is on identifying current and potential API manufacturers, key patent expirations, and regulatory considerations impacting market entry.

What is FERRLECIT API?

FERRLECIT is an intravenous iron replacement product used to treat iron deficiency anemia in adult patients with chronic kidney disease (CKD) who are undergoing hemodialysis. The API, Sodium Ferric Gluconate Complex, is a colloidal iron (III) hydroxide complex stabilized by a partially reduced, roasted starch. The chemical name is Iron(3+), gluconate-O1,O2-(4R,5R,6S)-5,6-dihydroxy-2-(hydroxymethyl)oxane-4-carboxylate, complex with hydroxide. Its molecular formula is C12H13FeNaO15 and its molecular weight is 550.08 g/mol.

The synthesis of Sodium Ferric Gluconate Complex involves precise control of pH, temperature, and reagent addition to ensure the formation of a stable colloidal complex with the desired particle size and iron content. This complexity in manufacturing contributes to the specialized nature of its API production.

Who Manufactures FERRLECIT API?

The primary manufacturer and originator of FERRLECIT is Vifor Pharma. Vifor Pharma, through its subsidiaries, holds significant intellectual property and manufacturing expertise for this specific API.

Current commercial supply is largely controlled by Vifor Pharma and its licensed partners. However, as patent protections expire and generic competition emerges, other API manufacturers are expected to enter or expand their presence. Identifying these potential manufacturers requires an analysis of regulatory filings, patent landscapes, and industry partnerships.

Key API Manufacturers and Potential Entrants

• Vifor Pharma: As the originator, Vifor Pharma maintains direct control over its API production. Their established Good Manufacturing Practices (GMP) facilities are a primary source.
• Potential Generic API Manufacturers: Companies specializing in complex iron-based APIs are candidates. These may include established players in the parenteral nutrition and injectable drug sectors. Specific companies that have demonstrated capabilities in producing complex colloidal iron APIs or have successfully launched generic injectable iron products globally represent strong potential entrants.

What is the Patent Landscape for FERRLECIT API?

The patent landscape for FERRLECIT API is critical for understanding market exclusivity and the timeline for generic entry. The primary patent protecting the composition of matter and its manufacturing process would have been filed around the time of its initial development.

Key Patents and Expiration Dates

• US Patent No. 5,658,591: This patent, titled "Iron-gluconate-hydroxide complexes," was granted on August 19, 1997, to VIROTEC Laboratories Pty. Ltd. (assignee). This patent covers the composition of the Sodium Ferric Gluconate Complex.
  • Expiration: The effective expiration date for this patent was August 19, 2014, considering its standard 20-year term from the filing date (which was typically much earlier than the grant date, often around 1994-1995 for this technology).
• Other Process Patents: While the composition of matter patent is paramount, Vifor Pharma may hold secondary patents related to specific manufacturing processes, purification techniques, or novel crystalline forms that could extend market exclusivity. Analysis of the Orange Book and global patent databases is necessary for a complete picture.

The expiration of key composition of matter patents opens the door for generic manufacturers. However, the complexity of the API and potential process patents can still present significant barriers to entry.

What are the Regulatory Considerations for FERRLECIT API?

Manufacturing and supplying FERRLECIT API requires strict adherence to regulatory guidelines to ensure product quality, safety, and efficacy.

Key Regulatory Requirements

• Good Manufacturing Practices (GMP): API manufacturers must comply with current Good Manufacturing Practices (cGMP) as mandated by regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other national health authorities. This includes stringent controls over raw materials, manufacturing processes, facility maintenance, quality control, and documentation.
• Drug Master Files (DMFs): API manufacturers typically submit Drug Master Files (DMFs) to regulatory agencies. A DMF contains confidential, detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drugs. This allows the FDA to review the API information in support of an Abbreviated New Drug Application (ANDA) filed by a finished dosage form manufacturer.
  • Vifor Pharma's DMF: Vifor Pharma likely maintains a DMF for its FERRLECIT API.
  • Generic DMFs: Generic API manufacturers must file their own DMFs to support their ANDA filings.
• Stability Studies: Manufacturers must conduct and provide comprehensive stability data for the API, demonstrating its shelf-life under specified storage conditions. This is critical for parenteral drugs.
• Impurity Profiling: Rigorous analytical testing is required to identify and quantify any impurities. This includes process-related impurities and degradation products. The acceptable limits for these impurities are defined by pharmacopeial standards and regulatory guidelines.
• Pharmacopeial Standards: The API must meet the specifications outlined in relevant pharmacopeias, such as the United States Pharmacopeia (USP) or the European Pharmacopoeia (Ph. Eur.). These monographs define identity, purity, strength, and quality attributes. For Sodium Ferric Gluconate Complex, specific tests for iron content, colloidal properties, pH, and absence of specific contaminants are crucial.

What is the Market Outlook for FERRLECIT API?

The market outlook for FERRLECIT API is influenced by several factors, including patent expirations, the emergence of generic competition, and the demand for intravenous iron therapies in CKD patients.

Demand and Competition Drivers

• Prevalence of CKD: The increasing global prevalence of chronic kidney disease, particularly among aging populations, drives demand for effective anemia management therapies, including intravenous iron.
• Generic Entry: The expiration of key patents for FERRLECIT has opened the market for generic versions. This will likely lead to price erosion and increased competition among API suppliers and finished dosage form manufacturers.
• Competition from Other IV Iron Products: FERRLECIT competes with other intravenous iron formulations, such as iron dextran, iron sucrose, ferric carboxymaltose, and ferumoxytol. The availability and pricing of these alternatives influence market share.
• Manufacturing Complexity: The specialized nature of Sodium Ferric Gluconate Complex API manufacturing, requiring expertise in colloidal chemistry and sterile processing, may limit the number of viable generic API producers. This could provide a sustained competitive advantage for established players with proven manufacturing capabilities.
• Therapeutic Equivalence: Generic products must demonstrate therapeutic equivalence to the reference listed drug (FERRLECIT). This requires rigorous clinical studies and bioequivalence trials.

Potential for New API Suppliers

The entry of new API suppliers depends on their ability to:

1. Develop a Robust Manufacturing Process: Replicate the complex synthesis of Sodium Ferric Gluconate Complex to meet stringent quality standards.
2. Achieve Regulatory Approval: Successfully file DMFs and have them accepted by major regulatory agencies.
3. Secure Partnerships: Collaborate with generic drug manufacturers seeking to launch ANDAs.
4. Compete on Price and Quality: Offer API at a competitive price point while maintaining high-quality standards.

The market is transitioning from a single-source originator to a multi-source generic environment. API manufacturers that can reliably produce high-quality Sodium Ferric Gluconate Complex at scale and with competitive cost structures will be well-positioned.

Key Takeaways

• Vifor Pharma is the primary originator and current key supplier of FERRLECIT API.
• Key composition of matter patents for FERRLECIT API have expired, paving the way for generic entry.
• The manufacturing of Sodium Ferric Gluconate Complex API is complex, requiring specialized expertise in colloidal chemistry and strict adherence to GMP.
• Regulatory compliance, including successful DMF filings and meeting pharmacopeial standards, is paramount for API suppliers.
• The increasing prevalence of CKD supports continued demand for intravenous iron therapies, creating opportunities for generic API manufacturers.
• Successful generic API suppliers will need to demonstrate manufacturing capability, regulatory adherence, and competitive pricing.

Frequently Asked Questions

What is the primary therapeutic indication for FERRLECIT API?

FERRLECIT API is used in the formulation of intravenous iron replacement products for the treatment of iron deficiency anemia in adult patients with chronic kidney disease undergoing hemodialysis.

Who is the originator of FERRLECIT?

The originator of FERRLECIT is Vifor Pharma.

When did the main composition of matter patent for FERRLECIT API expire?

The main US composition of matter patent (US Patent No. 5,658,591) expired in August 2014.

What are the key regulatory documents required for FERRLECIT API suppliers?

Key regulatory documents include compliance with current Good Manufacturing Practices (cGMP) and the submission of a Drug Master File (DMF) to regulatory agencies like the FDA and EMA.

What challenges do new API manufacturers face when entering the FERRLECIT market?

Challenges include replicating the complex manufacturing process to meet quality standards, navigating the regulatory approval process, demonstrating therapeutic equivalence of the final drug product, and competing on price with established suppliers.

Citations

[1] United States Patent 5,658,591. (1997, August 19). Iron-gluconate-hydroxide complexes. VIROTEC Laboratories Pty. Ltd. (Assignee). Retrieved from USPTO Patent Full-Text and Image Database [2] U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from FDA Orange Book